10:00 AM EDT, 07/22/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

After Q2 results, we adjust our 12-month target price to $230 from $240, 25.5x our 2026 EPS view, a discount to DHR's 5-year historical forward P/E average of 29.2x. We maintain our 2025 EPS estimate at $7.73. We lower our 2026 EPS view to $9.01 from to $9.19. Danaher's ( DHR ) Q2 results showed improvement despite a number of headwinds in the operating environment, in our view. Q2 sales climbed to $5.9B, up a solid 3.5% Y/Y. With continued momentum in bioprocessing, the Biotechnology segment led growth with an 8% Y/Y increase in revenue. This counterbalanced slower sales growth in the Life Sciences (+0.5% Y/Y) and the Diagnostics segments (+2.0% Y/Y). Looking ahead, despite a challenging macroeconomic environment, DHR sees Q3 core revenue growth in the low single digits, which we deem to be encouraging. DHR also kept its full-year 2025 core revenue growth at approximately 3% Y/Y. We pencil in $24.5B in total sales for 2025, which points to solid growth of 2.8% Y/Y in a tough operating environment.